Table 1 Participant screening stages and applied criteria.
Screening Stage | Formal Criteria Application | Clinician’s Expert Judgment (Manual Screening) |
|---|---|---|
1. Automated Screening | • Aged 50 years or older • Confirmed diagnosis of nAMD in at least one eye • Previously treated with at least three monthly intravitreal anti-VEGF injections (with drugs different from faricimab) • Injection interval approximately aligning with the trial’s window • Meeting broad visual acuity criteria • Absence of recent contraindicating surgery | (Not applicable) |
2. Manual Screening | • Demonstrates an ongoing need for treatment (i.e., incomplete or unstable disease control) | • Assessed sufficient media clarity and fixation: By scrutinizing recent OCT, fundus photos, and clinical notes for artifacts or pathologies that would preclude quality imaging. • Assessed Likely BCVA ≥ 24 letters: By reviewing recent visual acuity records from clinical notes. • Assessed ability and willingness for follow-up: By contacting the patient directly via telephone to confirm their commitment, logistical feasibility, and understanding of the study requirements. |
3. In-Person Screening | • Sufficient media clarity and fixation to permit high-quality imaging • BCVA of at least 24 ETDRS letters • Able and willing to attend regular follow-up visits for the 56-week study period | (Formal confirmation and final data collection at the visit) |
